TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Nordic Biolabs AB
Closing information (x1000 SEK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
111,454
|
114,966
|
117,875 |
| Financial expenses |
180
|
41
|
2 |
| Earnings before taxes |
-2,873
|
-1,450
|
6,039 |
| EBITDA |
-1,451
|
31
|
7,488 |
| Total assets |
38,735
|
35,287
|
37,330 |
| Current assets |
36,162
|
31,525
|
33,440 |
| Current liabilities |
25,655
|
23,279
|
20,869 |
| Equity capital |
13,014
|
11,294
|
15,417 |
| - share capital |
2,400
|
2,400
|
2,400 |
| Employees (average) |
30
|
28
|
25 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
33.6%
|
32.0%
|
41.3% |
| Turnover per employee |
3,715
|
4,106
|
4,715 |
| Profit as a percentage of turnover |
-2.6%
|
-1.3%
|
5.1% |
| Return on assets (ROA) |
-7.0%
|
-4.0%
|
16.2% |
| Current ratio |
141.0%
|
135.4%
|
160.2% |
| Return on equity (ROE) |
-22.1%
|
-12.8%
|
39.2% |
| Change turnover |
-3,512
|
-2,909
|
-16,408 |
| Change turnover % |
-3%
|
-2%
|
-12% |
| Chg. No. of employees |
2
|
3
|
2 |
| Chg. No. of employees % |
7%
|
12%
|
9% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.